Android app Apple app link

CIRM awards $8m grant to Tr1X for trial of GvHD prevention drug candidate TRX103

By Yahoo! Finance   |   1 week ago
CIRM awards $8m grant to Tr1X for trial of GvHD prevention drug candidate TRX103

The California Institute for Regenerative Medicine (CIRM) has granted $8m to Tr1X for their Phase I/IIa trial of TRX103, a drug to prevent GvHD in blood cancer patients undergoing stem cell transplants.

Read More

Did you find this insightful?

Premium Content

This content is only available for premium members. Please become a paid member to access.

Download App

Currently, memberships can only be purchased through the app.